188 related articles for article (PubMed ID: 32586771)
1. Correlation of platelet crossmatch results by Solid Phase Red Cell Adherence Assay (SPRCA) with post-transfusion platelet count increment in adult hemato-oncology patients of a tertiary care oncology centre in India.
Desai P; Sontakke P; Rajadhyaksha S; Navkudkar A
Transfus Apher Sci; 2020 Oct; 59(5):102842. PubMed ID: 32586771
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion.
Chavan A; Sharma RR; Saikia B; Malhotra P; Prakash S; Hans R; Marwaha N
Transfus Apher Sci; 2019 Dec; 58(6):102657. PubMed ID: 31706911
[TBL] [Abstract][Full Text] [Related]
3. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders.
Neanaey WA; Deghady AA; Nafea DA; Fahmy NM; Gouda AM
Oman Med J; 2022 Jul; 37(4):e402. PubMed ID: 35915764
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
6. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
7. Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.
Elhence P; Chaudhary RK; Nityanand S
Blood Transfus; 2014 Apr; 12(2):180-6. PubMed ID: 24333069
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
9. Effects of ABO Matching of Platelet Transfusions in Critically Ill Children.
Nellis ME; Goel R; Karam O; Cushing MM; Davis PJ; Steiner ME; Tucci M; Stanworth SJ; Spinella PC; ;
Pediatr Crit Care Med; 2019 Feb; 20(2):e61-e69. PubMed ID: 30422914
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Platelet Crossmatch Positivity and Predictive Value for Poor Platelet Increment Among Paediatric Oncohaematology Patients in India.
Kingsley S; Chacko MP; Amal P; Rebekah G; Leni GM; Dolly D
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):164-170. PubMed ID: 32174695
[TBL] [Abstract][Full Text] [Related]
11. Prospective platelet crossmatching for selection of compatible random donors.
Freedman J; Hooi C; Garvey MB
Br J Haematol; 1984 Jan; 56(1):9-18. PubMed ID: 6367808
[TBL] [Abstract][Full Text] [Related]
12. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
13. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.
Gelb AB; Leavitt AD
Transfusion; 1997 Jun; 37(6):624-30. PubMed ID: 9191823
[TBL] [Abstract][Full Text] [Related]
14. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
[TBL] [Abstract][Full Text] [Related]
15. [Can thrombocyte crossmatching improve the efficiency of platelet transfusion?].
Weisbach V; Zeiler T; Zingsem J; Musch R; Heuft HG; Eckstein R
Beitr Infusionsther; 1990; 26():160-2. PubMed ID: 1703820
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions.
Salama OS; Aladl DA; El Ghannam DM; Elderiny WE
Blood Transfus; 2014 Apr; 12(2):187-94. PubMed ID: 24931840
[TBL] [Abstract][Full Text] [Related]
17. ABO and platelet transfusion revisited.
Heal JM; Rowe JM; Blumberg N
Ann Hematol; 1993 Jun; 66(6):309-14. PubMed ID: 8318561
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
19. False-negative solid-phase platelet crossmatch results due to prozone phenomenon.
Horton RK; Zuccarelli MD; Wakefield LL; DiGuardo MA; Gandhi MJ; Juskewitch JE
Transfusion; 2020 Dec; 60(12):3055-3059. PubMed ID: 33047855
[TBL] [Abstract][Full Text] [Related]
20. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
